ReviewCurrent allergy and asthma reports2025
Hypereosinophilia in Children.
Review in Current allergy and asthma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHypereosinophilia is defined as an absolute eosinophil count greater than 1500 cells/mm3. This is a condition often observed in the pediatric population, with benign/self-resolving to life-threatening etiologies. Identifying the cause of hypereosinophilia can be challenging, given its broad associated differential diagnosis and diversity of presentations. This review provides an overview of eosinophil biology and explores causes of hypereosinophilia in children, emphasizing diagnostic and therapeutic challenges, while underscoring the importance of recognizing rare causes including primary hypereosinophilic syndrome (HES). RECENT
findingsClassification of hypereosinophilic subtypes has evolved, as has understanding of etiologies with advances in modern diagnostic tools. Newer therapeutic options with low side-effect profiles have expanded treatment options in patients with HES. Despite recent improvements in medical management, HES remains a serious medical condition with considerable morbidity and potential mortality. Early identification and appropriate treatment can improve prognosis and reduce the burden of disease in children.
Indexed as
Identifiers
40407964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.